DPP-4 inhibitors in the treatment of type 2 diabetes
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
Although being a primary objective in the management of type 2 diabetes, optimal glycaemic control is difficult to achieve and usually not maintained over time. Type 2 diabetes is a complex pathology, comprising altered insulin sensitivity and impaired insulin secretion. Recent advances in the understanding of the physiological functions of incretins and their degrading enzyme dipeptidyl-peptidase (DPP)-4 have led to the 'discovery' of a new class of oral anti-diabetic drugs. Several DPP-4 inhibitors (or gliptins) with different chemical structures are now available. These agents inhibit the degradation of the incretins glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) and hence potentiate glucose-dependent insulin secretion. DPP-4 inhibitors inhibit DPP-4 activity by almost 100% in vitro, maintaining a ≥ 80% inhibition throughout the treatment period in vivo, thus prolonging GLP-1 half-life, and significantly reducing HbA1c generally by -0.7 to 0.8% as well as fasting and post-prandial glycaemia. They are well-tolerated with no weight gain and few adverse effects, and, of particular interest, no increase in hypoglycaemic episodes. Although different by their chemical structure and pharmacokinetic properties, the DPP4 inhibitors currently available have proven similar glucose lowering efficacy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
Biology of Incretins: GLP-1 and GIP
Baggio, L. L., & Drucker, D. J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.054 · Cited by 3,639 · cited 3×
“However, it does not inhibit glucagon secretion nor does it modulate gastric emptying [13].”
BackgroundInfluentialGlycemic durability of rosiglitazone, metformin, or glyburide monotherapy
Kahn, S. E., Haffner, S. M., Heise, M. A., Herman, W. H., Holman, R. R., Jones, N. P., Kravitz, B. G., Lachin, J. M., O'Neill, M. C., Zinman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa066224 · Cited by 2,962
Reduced incretin effect in Type 2 (non-insulin dependent) diabetes
Nauck, M., Stöckmann, F., Ebert, R., & Creutzfeldt, W. (1986) · Diabetologia · doi:10.1007/bf02427280 · Cited by 1,307 · cited 1×
“Several reports suggest that the incretin effect is reduced in type 2 diabetic patients [21] [22], although recent studies indicate that the reduction of insulin secretion is primarily due to an impairment in β-cell function after chronic hyperglycaemia rather than a primary defect in glucose-dependent GLP-1 and GIP a…”
BackgroundInhibition of gastric inhibitory polypeptide signaling prevents obesity
Miyawaki, K., Yamada, Y., Ban, N., Ihara, Y., Tsukiyama, K., Zhou, H., Fujimoto, S., Oku, A., Tsuda, K., Toyokuni, S., et al. (2002) · Nature Medicine · doi:10.1038/nm727 · Cited by 963 · cited 1×
“Accordingly, GIP-receptor-deficient mice have defective insulin secretion in response to oral glucose [18], but resist to the development of diet- or genetically-induced obesity and have improved insulin sensitivity [19].”
BackgroundDrucker, D. J., Philippe, J., Mojsov, S., Chick, W. L., & Habener, J. F. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.10.3434 · Cited by 903 · cited 1×
“Indeed, GLP-1 and GIP stimulate β-cell insulin secretion [11;12].”
BackgroundNikolaidis, L. A., Mankad, S., Sokos, G. G., Miske, G., Shah, A., Elahi, D., & Shannon, R. P. (2004) · Circulation · doi:10.1161/01.cir.0000120505.91348.58 · Cited by 901 · cited 1×
“On the one hand, continuous IV administration of GLP-1 in cardiac insufficiency and myocardial infarction improves cardiac function by increasing left ventricular ejection fraction [94].”
BackgroundNAUCK, M. A., HOMBERGER, E., SIEGEL, E. G., ALLEN, R. C., EATON, R. P., EBERT, R., & CREUTZFELDT, W. (1986) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-63-2-492 · Cited by 874 · cited 1×
“The ‘incretin effect’: physiological basis The term ‘incretin effect’ has been coined to describe stimulated insulin secretion after oral glucose ingestion compared to isoglycaemic parenteral or iv glucose administration [4].”
BackgroundSTIMULATION OF INSULIN SECRETION BY GASTRIC INHIBITORY POLYPEPTIDE IN MAN. 1
Dupre, J., Ross, S. A., Watson, D., & Brown, J. C. (1973) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-37-5-826 · Cited by 860
Charbonnel, B., Karasik, A., Liu, J., Wu, M., Meininger, G., & for the Sitagliptin Study 020 Group (2006) · Diabetes Care · doi:10.2337/dc06-0706 · Cited by 790
Cited by
Autoimmune Aspects of Type 2 Diabetes Mellitus - A Mini-Review
Itariu, B. K., & Stulnig, T. M. (2014) · Gerontology · doi:10.1159/000356747 · Cited by 107
Jalaludin, M. Y., Deeb, A., Zeitler, P., Garcia, R., Newfield, R. S., Samoilova, Y., Rosario, C. A., Shehadeh, N., Saha, C. K., Zhang, Y., et al. (2022) · Pediatric Diabetes · doi:10.1111/pedi.13282 · Cited by 31
Guan, C., Luo, J., Li, S., Tan, Z. L., Wang, Y., Chen, H., Yamamoto, N., Zhang, C., Lu, Y., Chen, J., et al. (2023) · ACS Omega · doi:10.1021/acsomega.3c05571 · Cited by 13
Metadata
- Authors
- Duez, H., Cariou, B., & Staels, B.
- Venue
- Biochemical Pharmacology
- Publisher
- Elsevier BV
- Published
- 2012-04
- Volume
- 83
- Issue
- 7
- Pages
- 823-832
- ISSN
- 0006-2952 (ISSN-L)
- OpenAlex
- W2045799771
- Cited by
- 110
- References
- 22
- FWCI
- 5.41
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: DPP-4 inhibitors in the treatment of type 2 diabetes. https://app.cochat.ai/papers/10.1016/j.bcp.2011.11.028
- The paper
- Duez, H., Cariou, B., & Staels, B. (2012). DPP-4 inhibitors in the treatment of type 2 diabetes. Biochemical Pharmacology. https://doi.org/10.1016/j.bcp.2011.11.028
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.